Araceli Biosciences Integrates Endeavor Imaging System into Ginkgo Bioworks’ Nebula Lab

PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /CourierPR/ -- Araceli Biosciences and Ginkgo Bioworks have integrated Araceli’s Endeavor high-content imaging instrument into Ginkgo’s autonomous lab, Nebula, in Boston. This integration aims to enhance the lab’s capabilities in generating cellular data at scale, providing researchers with the large, curated datasets necessary for training and validating drug discovery AI models.

Nebula, built on Ginkgo’s Reconfigurable Automation Carts (RACs), is an autonomous lab that operates 24/7, using around a third of the space required by traditional lab benches. Each RAC combines robotic arms, automated sample transport, and unified control software, allowing for the seamless addition and rearrangement of instruments as workflows change. Currently, dozens of scientists use the 100+ RACs on Nebula for real research, submitting protocols and receiving their data the next day.

The Endeavor, the world’s fastest high-content imaging system, can image a 1536-well plate in under four minutes. With Araceli’s ClaireRT™ software, the Endeavor analyzes every well as the image is captured. When a well falls outside defined criteria, the system can alert operators or Nebula, or halt imaging to address issues before the experiment continues.

Araceli Biosciences develops the world's fastest high-content imaging instruments and AI-powered analysis software for automated, AI-driven labs. Its integrated solutions deliver real-time cellular insights that let automated workflows check quality and make decisions at every stage of an experiment, helping biotech and pharma organizations scale discovery faster and with greater confidence.

Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through its Datapoints and Solutions contract research services.

According to Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026, the integration of the Endeavor into Nebula represents a significant step in advancing drug discovery through high-content imaging and real-time analysis.